CN105592849A - 用于减轻神经系统损伤的组合物及该组合物的制造方法和用途 - Google Patents

用于减轻神经系统损伤的组合物及该组合物的制造方法和用途 Download PDF

Info

Publication number
CN105592849A
CN105592849A CN201380079011.7A CN201380079011A CN105592849A CN 105592849 A CN105592849 A CN 105592849A CN 201380079011 A CN201380079011 A CN 201380079011A CN 105592849 A CN105592849 A CN 105592849A
Authority
CN
China
Prior art keywords
amiloride
analog
pharmaceutical composition
amiloride analog
guanidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380079011.7A
Other languages
English (en)
Chinese (zh)
Inventor
熊志刚
罗杰·P·西蒙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morehouse School of Medicine Inc
Original Assignee
Morehouse School of Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morehouse School of Medicine Inc filed Critical Morehouse School of Medicine Inc
Priority to CN201910276187.0A priority Critical patent/CN110742891B/zh
Publication of CN105592849A publication Critical patent/CN105592849A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201380079011.7A 2013-08-21 2013-08-21 用于减轻神经系统损伤的组合物及该组合物的制造方法和用途 Pending CN105592849A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910276187.0A CN110742891B (zh) 2013-08-21 2013-08-21 用于减轻神经系统损伤的组合物及该组合物的制造方法和用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2013/056011 WO2015026339A1 (en) 2013-08-21 2013-08-21 Composition for reducing nervous system injury and method of making and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910276187.0A Division CN110742891B (zh) 2013-08-21 2013-08-21 用于减轻神经系统损伤的组合物及该组合物的制造方法和用途

Publications (1)

Publication Number Publication Date
CN105592849A true CN105592849A (zh) 2016-05-18

Family

ID=52483995

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380079011.7A Pending CN105592849A (zh) 2013-08-21 2013-08-21 用于减轻神经系统损伤的组合物及该组合物的制造方法和用途
CN201910276187.0A Active CN110742891B (zh) 2013-08-21 2013-08-21 用于减轻神经系统损伤的组合物及该组合物的制造方法和用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910276187.0A Active CN110742891B (zh) 2013-08-21 2013-08-21 用于减轻神经系统损伤的组合物及该组合物的制造方法和用途

Country Status (5)

Country Link
EP (1) EP3035931B1 (enExample)
JP (1) JP2016528283A (enExample)
CN (2) CN105592849A (enExample)
HK (1) HK1221911A1 (enExample)
WO (1) WO2015026339A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112717135A (zh) * 2016-11-22 2021-04-30 上海交通大学医学院 酸敏感离子通道调控剂的用途
CN112888312A (zh) * 2018-08-28 2021-06-01 莫尔豪斯医学院 用于预防或降低短暂性脑缺血发作发病率的组合物及方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105412932B (zh) * 2015-10-26 2019-08-16 上海交通大学医学院 含ASIC1a与RIP1结合抑制剂的制剂及其抑制神经元死亡的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080242588A1 (en) * 2006-11-21 2008-10-02 Legacy Emanuel Hospital & Health Center System for seizure suppression
US20110312902A1 (en) * 2005-07-01 2011-12-22 Rosalind Franklin University Of Medicine And Science Cytoprotective thereapeutic agents for the prevention of reperfusion injury following ischemic stroke

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0789859A (ja) * 1990-04-05 1995-04-04 Celtrix Pharmaceut Inc ピラジン誘導体を含む薬剤学的組成物と眼の新血管新生を阻止する治療法
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US7470718B2 (en) * 2000-10-03 2008-12-30 Albert Einstein College Of Medicine Of Yeshiva University Method for treating a demyelinating condition
ES2339790T3 (es) * 2004-08-30 2010-05-25 Seo Hong Yoo Efecto neuroprotector de udca solubilizado en modelo isquemico focal.
US8030442B2 (en) 2004-09-16 2011-10-04 Morehouse School Of Medicine Treatment of injury to the brain by inhibition of acid sensing ion channels
CA2622890A1 (en) * 2004-09-16 2006-03-30 Virogenomics, Inc. Treatment of ischemia
JP2008222603A (ja) * 2007-03-09 2008-09-25 Institute Of Physical & Chemical Research 神経変性疾患の予防・治療剤
US20090062309A1 (en) 2007-08-28 2009-03-05 Antonio Delgado-Almeida Therapeutic compositions for the treatment of cardiovascular diseases and methods for use therefor
WO2009140568A1 (en) * 2008-05-15 2009-11-19 The Coca-Cola Company Natural and/or synthetic high-potency sweetener compositions with improved temporal profile and/or flavor profile, methods for their formulation, and uses
EP2322149A1 (en) * 2009-11-03 2011-05-18 Universidad del Pais Vasco Methods and compositions for the treatment of ischemia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110312902A1 (en) * 2005-07-01 2011-12-22 Rosalind Franklin University Of Medicine And Science Cytoprotective thereapeutic agents for the prevention of reperfusion injury following ischemic stroke
US20080242588A1 (en) * 2006-11-21 2008-10-02 Legacy Emanuel Hospital & Health Center System for seizure suppression

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AT BEHAN 等: ""Acidotoxicity and acid-sensing ion channels contribute to motoneuron degeneration"", 《CELL DEATH AND DIFFERENTIATION》 *
JULIO SANTOS-TORRES 等: ""Cross-reactivity of acid-seensing ion channel and Na+-H+ exchanger antagonists with nicotinic acetylcholine receptors"", 《THE JOURNAL OF PHYSIOLOGY》 *
叶抗 等: ""阿米洛利的神经保护作用"", 《国际脑血管病杂志》 *
叶抗 等: "阿米洛利的神经保护作用", 《国际脑血管病杂志》 *
李雪卿: "阿米洛利对大鼠全脑缺血/再灌注损伤的影响", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 *
程慧娴 等: "酸敏感离子通道在缺血性脑损伤中的作用", 《国际麻醉学与复苏杂志》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112717135A (zh) * 2016-11-22 2021-04-30 上海交通大学医学院 酸敏感离子通道调控剂的用途
CN112888312A (zh) * 2018-08-28 2021-06-01 莫尔豪斯医学院 用于预防或降低短暂性脑缺血发作发病率的组合物及方法
CN114712361A (zh) * 2018-08-28 2022-07-08 莫尔豪斯医学院 用于预防或降低短暂性脑缺血发作发病率的组合物及方法

Also Published As

Publication number Publication date
HK1221911A1 (zh) 2017-06-16
JP2016528283A (ja) 2016-09-15
WO2015026339A1 (en) 2015-02-26
EP3035931A1 (en) 2016-06-29
EP3035931A4 (en) 2017-05-31
CN110742891B (zh) 2024-04-05
CN110742891A (zh) 2020-02-04
EP3035931B1 (en) 2020-03-11

Similar Documents

Publication Publication Date Title
US11826366B2 (en) Composition and methods for preventing or reducing the incidence of transient ischemic attacks
US11559524B2 (en) Composition for reducing nervous system injury and method of making and use thereof
US10766936B2 (en) Treatment of ischemia
US11802140B2 (en) Treatment of ischemia
HK1247847A1 (zh) 四氢-N，N-二甲基-2，2-二苯基-3-呋喃甲胺的对映体(ANAVEX2-73)及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途
CN110742891B (zh) 用于减轻神经系统损伤的组合物及该组合物的制造方法和用途
CN114712361A (zh) 用于预防或降低短暂性脑缺血发作发病率的组合物及方法
JP2020079289A (ja) 神経系損傷を減少させるための組成物及びその製造方法及び使用
JP2018138592A (ja) 神経系損傷を減少させるための組成物及びその製造方法及び使用
JP7706376B2 (ja) 神経修復方法
HK40020385A (en) Composition for reducing nervous system injury and method of making and use thereof
Tochitsky et al. Inhibiting cough by silencing large pore-expressing airway sensory neurons with a charged sodium channel blocker

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1221911

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160518

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1221911

Country of ref document: HK